Want to buy Clovis? Step up. ‘Everybody knows where to find me,’ CEO says

Shortly after GlaxoSmithKline bought PARP-inhibitor innovator Tesaro for $5.1 billion in early December, analysts started buzzing about the likelihood that Clovis Oncology would be the next PARP player to get scooped up at a high premium.

Now Clovis CEO Patrick Mahaffy is making it clear he’s ready to deal.